Editas Medicine : October 2019 Corporate Presentation

Corporate Presentation

October 7, 2019

P I O N E E R I N G T H E P O S S I B L E

editasmedicine.com

© 2019 Editas Medicine

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of The Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this presentation, including statements

regarding the Company's strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, and

objectives of management, are forward-looking statements. The words ''anticipate,'' ''believe,'' ''continue,'' ''could,'' ''estimate,'' ''expect,'' ''intend,'' ''may,'' ''plan,'' ''potential,'' ''predict,'' ''project,'' ''target,'' ''should,'' ''would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this presentation include statements regarding the clinical trial timeline for EDIT-101(AGN-151587) and the Company's 2022 goals. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should

not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions

and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company's product candidates; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other factors discussed in the "Risk Factors" section of the Company's

most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the

Company may make with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation.

© 2019 Editas Medicine

2

Transforming Patient Lives

OUR MISSION

is to translate the promise of genome editing into a broad class of transformative

genomic medicines to benefit the greatest number of patients

© 2019 Editas Medicine

3

Pioneering the Possible

Clinical-stage company

working to transform

patient lives

• First in vivo CRISPR clinical trial in history (EDIT-101 for LCA10)
• EDIT-101patient screening initiated and dosing on track for 2H19
• Rapidly translating exciting science into revolutionary medicines

Leader across CRISPR in vivo and engineered cell medicines

• Proven AAV delivery capability for in vivo CRISPR medicines
• Advancing engineered cell medicines to treat blood diseases and cancer
• Enabled by unparalleled platform of Cas9 and Cpf1 (Cas12a) enzymes

Strong progress

towards EM22

goals

• EDIT-101IND accepted by FDA upon initial review
• Usher syndrome 2A (USH2A) in vivo proof of concept established
• EDIT-301for sickle cell and beta-thalassemia IND- enabling activities initiated

editasmedicine.com

© 2019 Editas Medicine

4

2019 Achievements and Goals

ACHIEVEMENTS		GOALS
✓ Formed collaboration with		EDIT-101 first patient
BlueRock Therapeutics to		dosing in second half
advance universal allogeneic
cell medicines for cancer

• Initiated IND-enabling activities for EDIT-301 for sickle cell and beta-thalassemia
• Established in vivo proof-of-concept for Usher syndrome 2A

EDIT-301pre-clinical data in second half

Usher syndrome 2A ready for IND-enabling studies by year-end

© 2019 Editas Medicine

5